Pharming Group Statistics
Total Valuation
Pharming Group has a market cap or net worth of $920.47 million. The enterprise value is $865.32 million.
| Market Cap | 920.47M |
| Enterprise Value | 865.32M |
Important Dates
The last earnings date was Thursday, May 7, 2026, before market open.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Pharming Group has 744.71 million shares outstanding. The number of shares has increased by 13.48% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 744.71M |
| Shares Change (YoY) | +13.48% |
| Shares Change (QoQ) | -1.64% |
| Owned by Insiders (%) | 1.55% |
| Owned by Institutions (%) | 22.84% |
| Float | 695.28M |
Valuation Ratios
The trailing PE ratio is 800.65 and the forward PE ratio is 58.76.
| PE Ratio | 800.65 |
| Forward PE | 58.76 |
| PS Ratio | 2.49 |
| Forward PS | 2.77 |
| PB Ratio | 3.42 |
| P/TBV Ratio | 6.67 |
| P/FCF Ratio | 16.52 |
| P/OCF Ratio | 16.31 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 20.47, with an EV/FCF ratio of 15.53.
| EV / Earnings | 70.03 |
| EV / Sales | 2.34 |
| EV / EBITDA | 20.47 |
| EV / EBIT | 24.80 |
| EV / FCF | 15.53 |
Financial Position
The company has a current ratio of 2.63, with a Debt / Equity ratio of 0.43.
| Current Ratio | 2.63 |
| Quick Ratio | 2.05 |
| Debt / Equity | 0.43 |
| Debt / EBITDA | 2.54 |
| Debt / FCF | 2.09 |
| Interest Coverage | 4.20 |
Financial Efficiency
Return on equity (ROE) is 5.04% and return on invested capital (ROIC) is 10.00%.
| Return on Equity (ROE) | 5.04% |
| Return on Assets (ROA) | 4.89% |
| Return on Invested Capital (ROIC) | 10.00% |
| Return on Capital Employed (ROCE) | 9.25% |
| Weighted Average Cost of Capital (WACC) | 4.85% |
| Revenue Per Employee | $907,830 |
| Profits Per Employee | $30,361 |
| Employee Count | 407 |
| Asset Turnover | 0.83 |
| Inventory Turnover | 0.71 |
Taxes
In the past 12 months, Pharming Group has paid $7.67 million in taxes.
| Income Tax | 7.67M |
| Effective Tax Rate | 38.57% |
Stock Price Statistics
The stock price has increased by +30.71% in the last 52 weeks. The beta is 0.12, so Pharming Group's price volatility has been lower than the market average.
| Beta (5Y) | 0.12 |
| 52-Week Price Change | +30.71% |
| 50-Day Moving Average | 16.08 |
| 200-Day Moving Average | 15.62 |
| Relative Strength Index (RSI) | 33.40 |
| Average Volume (20 Days) | 11,797 |
Short Selling Information
The latest short interest is 9,179, so 0.00% of the outstanding shares have been sold short.
| Short Interest | 9,179 |
| Short Previous Month | 12,882 |
| Short % of Shares Out | 0.00% |
| Short % of Float | 0.00% |
| Short Ratio (days to cover) | 0.40 |
Income Statement
In the last 12 months, Pharming Group had revenue of $369.49 million and earned $12.36 million in profits. Earnings per share was $0.02.
| Revenue | 369.49M |
| Gross Profit | 325.67M |
| Operating Income | 34.89M |
| Pretax Income | 19.88M |
| Net Income | 12.36M |
| EBITDA | 42.28M |
| EBIT | 34.89M |
| Earnings Per Share (EPS) | $0.02 |
Balance Sheet
The company has $170.18 million in cash and $116.21 million in debt, with a net cash position of $53.97 million or $0.07 per share.
| Cash & Cash Equivalents | 170.18M |
| Total Debt | 116.21M |
| Net Cash | 53.97M |
| Net Cash Per Share | $0.07 |
| Equity (Book Value) | 268.96M |
| Book Value Per Share | 0.36 |
| Working Capital | 183.17M |
Cash Flow
In the last 12 months, operating cash flow was $56.43 million and capital expenditures -$705,000, giving a free cash flow of $55.72 million.
| Operating Cash Flow | 56.43M |
| Capital Expenditures | -705,000 |
| Depreciation & Amortization | 7.39M |
| Net Borrowing | -16.51M |
| Free Cash Flow | 55.72M |
| FCF Per Share | $0.07 |
Margins
Gross margin is 88.14%, with operating and profit margins of 9.44% and 3.34%.
| Gross Margin | 88.14% |
| Operating Margin | 9.44% |
| Pretax Margin | 5.38% |
| Profit Margin | 3.34% |
| EBITDA Margin | 11.44% |
| EBIT Margin | 9.44% |
| FCF Margin | 15.08% |
Dividends & Yields
Pharming Group does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -13.48% |
| Shareholder Yield | -13.48% |
| Earnings Yield | 1.34% |
| FCF Yield | 6.05% |
Analyst Forecast
The average price target for Pharming Group is $38.33, which is 194.85% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $38.33 |
| Price Target Difference | 194.85% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 16.52% |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Pharming Group has an Altman Z-Score of 3.19 and a Piotroski F-Score of 5.
| Altman Z-Score | 3.19 |
| Piotroski F-Score | 5 |